NCT03982992 2024-03-12
DLI-TARGET
Ludwig-Maximilians - University of Munich
Phase 2 Withdrawn
Clinical Trials
6 trialsNCT04448834 2022-03-02
Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL
Duke University
Phase 2 Withdrawn
NCT03605589 2021-04-01
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
Children's Hospital Medical Center, Cincinnati
Phase 1 Withdrawn
NCT03628053 2020-07-09
OBERON
Novartis
Phase 3 Withdrawn
NCT00538096 2008-09-05
A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma
MedImmune LLC
Phase 1 Withdrawn
NCT00676871 2008-09-05
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)
MedImmune LLC
Phase 1/2 Withdrawn